Sponsors (3)
The bill aims to simplify and contain Medicare spending for skin substitutes and make payments more predictable (benefiting beneficiaries, hospitals, and taxpayers), but does so at the risk of reduced product availability, constrained clinician choice, lower manufacturer revenues (potentially harming innovation), and reduced price transparency.
Medicare beneficiaries with chronic, non‑healing wounds are more likely to get coverage that reflects clinical value for skin substitutes, improving access to appropriate therapies.
Reforming payment rules and consolidating reimbursement could lower Medicare spending on skin substitutes and reduce future cost growth for taxpayers and beneficiaries.
Medicare beneficiaries and hospitals will face more predictable, consolidated payments (starting Jan 1, 2026), simplifying billing and reimbursement administration.
Medicare beneficiaries and patients with chronic wounds could face reduced availability of certain skin substitute products and higher out‑of‑pocket costs if reimbursement restrictions lead providers to stop using uncovered items.
Lower, volume‑weighted consolidated payments may reduce reimbursement for some manufacturers and suppliers, risking decreased product supply, reduced competition, or less investment and innovation in skin substitute products.
Standardizing payments and relying on price‑based approaches could limit clinician flexibility and individualized product selection if narrow coverage rules or formularies replace tailored choices.
Based on analysis of 3 sections of legislative text.
Creates a single Medicare billing/payment code for skin substitutes with a Jan 1, 2026 volume‑weighted baseline from Oct–Dec 2023 data and annual CPI‑U updates from 2027.
Introduced July 31, 2025 by Bill Cassidy · Last progress July 31, 2025
Creates a single, consolidated Medicare billing and payment method for all skin substitute products used to treat chronic, non‑healing wounds, effective January 1, 2026. The payment amount will be set as a volume‑weighted average based on Medicare payment allowances and units billed Oct–Dec 2023, with annual updates beginning in 2027 tied to CPI‑U. The Secretary must establish a new consolidated billing/payment code and manufacturers of these products are exempted from certain Average Sales Price (ASP) reporting requirements. The bill keeps standard Medicare "reasonable and necessary" coverage rules but limits the Secretary's ability to deny coverage solely on clinical evidence analysis, except where safety concerns (contamination, infection, serious adverse reactions) arise.